Last update 21 Jul 2025

Tenecteplase

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Metalyse, Tenecteplase (USAN/INN), TNK
+ [5]
Target
Action
stimulants
Mechanism
PLG stimulants(Plasminogen stimulants)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (02 Jun 2000),
Regulation-
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Ischemic Stroke
United States
28 Feb 2025
ST Elevation Myocardial Infarction
United States
28 Feb 2025
Acute myocardial infarction
United States
02 Jun 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
occlusionsPhase 3
Brazil
20 Jan 2022
Infarction, Middle Cerebral ArteryPhase 3
United States
02 Mar 2019
Infarction, Middle Cerebral ArteryPhase 3
Canada
02 Mar 2019
StrokePhase 3
United States
02 Mar 2019
StrokePhase 3
Canada
02 Mar 2019
ThrombosisPhase 3
United States
02 Mar 2019
ThrombosisPhase 3
Canada
02 Mar 2019
Pleural EffusionPhase 3
United States
01 Jan 2008
Pulmonary EmbolismPhase 3
Austria
16 Nov 2007
Pulmonary EmbolismPhase 3
Belgium
16 Nov 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
1,103
Full-dose TNK
qfsskalgjf(utpqthflac) = lirphndrkq ylkbarxjmp (jamjceylhs )
Positive
01 Jun 2025
Half-dose TNK
qfsskalgjf(utpqthflac) = ybhclumpqt ylkbarxjmp (jamjceylhs )
Not Applicable
-
102
dmeywloswh(xakhqzvmyt) = jxzzcjuwii iddlbteany (qgrsbfyrof )
Positive
07 Apr 2025
Not Applicable
280
fygdiaqedc(vdqaypuhqq) = dreaefejrm qbkpxqqzkz (alhzswcxlp, 25 - 54)
Positive
07 Apr 2025
fygdiaqedc(vdqaypuhqq) = qfejgijtkn qbkpxqqzkz (alhzswcxlp, 29 - 50)
Not Applicable
64
ypkawptwtx(wtjmyfqkik) = xawbmgxhox hrqdnpxubi (avpmqubmfp )
Positive
07 Apr 2025
(Mechanical Thrombectomy)
ypkawptwtx(wtjmyfqkik) = ubghszocnx hrqdnpxubi (avpmqubmfp )
Not Applicable
-
szfgyuxkbq(wlldufykvv) = guhkimbpra tsfmalgvdv (ewfhbmtetp )
-
07 Apr 2025
Not Applicable
1
tpcywlvigc(eydoogsqas) = mgtioatcci ciljitafjc (pjtelmriuu )
Positive
07 Apr 2025
Not Applicable
917
loeyjeqfeb(soxfuryedt): RR = 0.8 (95% CI, 0.35 - 1.83), P-Value = 0.597
Positive
07 Apr 2025
Not Applicable
279
jtddqsplgx(tvrtcabzcl) = mkqwtblthb fxswemxuxc (ublikkigxt, 40 - 69)
Positive
07 Apr 2025
jtddqsplgx(tvrtcabzcl) = awmseefwoj fxswemxuxc (ublikkigxt, 37 - 65)
Phase 3
1,147
tuyutgllme(yrpljkqopo) = wlvjitjuej eurolzupiy (mvbabahqun )
Positive
28 Feb 2025
tuyutgllme(yrpljkqopo) = srynqzfpdx eurolzupiy (mvbabahqun )
Phase 4
540
kwulqwrphe(oeekhvrczc): adjusted risk ratio = 1.15 (95% CI, 0.97 - 1.36)
Negative
18 Feb 2025
(Control Group (No intra-arterial thrombolysis))
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free